Core Insights - The company is focusing on strategic transformation of its marketing system since 2025, combining product focus and channel optimization to enhance brand value and market competitiveness [1][5] - The company has established a multi-layered product matrix around key products, which includes nearly 300 varieties, laying a foundation for brand value release [1] - The optimization of channels is a key aspect of the marketing reform, with measures implemented to control channels and terminals, resulting in a more efficient sales network [1][5] Product Development - The company is concentrating on core products such as An Gong Niu Huang Wan, Xi Huang Wan, Liu Wei Di Huang Wan, and Jing Zhi Niu Huang Jie Du Wan, among others [1] - A systematic review of nearly 300 product varieties has been conducted to enhance product competitiveness [1] Channel Optimization - In 2025, the company implemented six targeted measures centered on "controlling channels and terminals," which include strengthening distributor admission and dynamic management [1] - The optimization of first and second-level distributors has achieved preliminary results, creating a "flat, efficient, and scientifically controllable" sales network [1] Terminal Network Development - The company has conducted 1,759 market activities, including 177 in prefecture-level cities, 100 in county areas, and 1,482 in communities, successfully developing 22 blank markets in counties [2][3] - Sales in grassroots markets have significantly increased year-on-year, with a notable rise in the proportion of terminal customers, particularly from third and fourth-tier cities and rural areas [2] "Double Thousand Project" - The company has established a terminal network covering 31 provinces and 273 prefecture-level cities, reaching over 230,000 chain and terminal stores [4] - The "Double Thousand Project" focuses on empowering 1,000 pharmacies and 1,000 medical clinics, enhancing product management, professional services, and brand marketing [4][5] - The project aims to improve product coverage and market responsiveness through resource packages that include priority supply guarantees and health culture lectures [4]

Group 1 - The core viewpoint of the news is that Tongrentang Technology (01666.HK) reported its unaudited financial results for the nine months ending September 30, 2025, showing significant revenue and profit figures [1] - The unaudited operating revenue for the group was approximately RMB 4.98 billion, with an operating cost of about RMB 2.991 billion, resulting in a net profit attributable to the parent company of approximately RMB 416 million [1] - As of September 30, 2025, the total unaudited assets of the group were approximately RMB 14.596 billion [1] Group 2 - As of October 28, 2025, Tongrentang Technology's stock closed at HKD 4.63, down 0.64%, with a trading volume of 1.5952 million shares and a trading value of HKD 7.3941 million [1] - Investment banks primarily rate the stock as outperforming the industry, with one bank giving an outperform rating in the last 90 days and a target average price of HKD 6.3 [1] - CITIC Securities recently issued a buy rating for Tongrentang Technology [1] Group 3 - The market capitalization of Tongrentang Technology is HKD 2.93 billion, ranking 6th in the Chinese medicine II industry [2] - Key performance indicators show that the company's ROE is 5.92%, which is higher than the industry average of 5.51% [2] - The company's net profit margin is 12.95%, slightly below the industry average of 13.75%, and its gross profit margin is 38.16%, significantly lower than the industry average of 51.2% [2]

Core Viewpoint - Tong Ren Tang Technologies (600085) reported its financial results for the nine months ending September 30, 2025, indicating a strong revenue performance and profitability [1] Financial Performance - The group's unaudited revenue for the nine months was approximately RMB 4.98 billion [1] - The unaudited cost of goods sold was approximately RMB 2.991 billion [1] - The unaudited net profit attributable to the owners of the parent company was approximately RMB 416 million [1] - As of September 30, 2025, the group's unaudited total assets were approximately RMB 14.596 billion [1]

Core Viewpoint - Tongrentang Technology (01666) reported its financial results for the nine months ending September 30, 2025, showing significant revenue and profit figures [1] Financial Performance - The company's unaudited operating revenue reached approximately RMB 4.98 billion for the nine months ending September 30, 2025 [1] - The unaudited operating costs for the same period were approximately RMB 2.991 billion [1] - The unaudited net profit attributable to the parent company was approximately RMB 416 million [1] - As of September 30, 2025, the company's unaudited total assets amounted to approximately RMB 14.596 billion [1]

Core Viewpoint - Tongrentang Technology (01666.HK) reported its financial results for the nine months ending September 30, 2025, showing significant revenue and profit figures [1] Financial Performance - The company recorded an unaudited revenue of approximately RMB 497,964 million for the nine months ending September 30, 2025 [1] - The unaudited cost of goods sold was approximately RMB 299,069 million during the same period [1] - The unaudited net profit attributable to the owners of the parent company was approximately RMB 41,626 million [1] - As of September 30, 2025, the company's unaudited total assets amounted to approximately RMB 1,459,589 million [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部 或任何部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 有關二零二五年三季度財務信息之公告 北京同仁堂科技發展股份有限公司（「本公司」）根據《證券及期貨條例》（香 港法例第571章）第XIVA部及香港聯合交易所有限公司證券上市規則第13.09條 作出本公告。 張毅 董事長 （股份代號：1666） 本公司控股股東北京同仁堂股份有限公司將於二零二五年十月三十一日在上海 證券交易所公佈其截至二零二五年九月三十日止九個月未經審計之三季度業 績，該業績包含本公司及其附屬公司（「本集團」）截至二零二五年九月三十日 止九個月未經審計的財務信息。為保證本公司全體股東公平、及時地知曉本公司 信息，本公司特此公佈以下財務信息：根據中華人民共和國財政部頒佈的《中華 人民共和國企業會計準則》，截至二零二五年九月三十日止九個月，本集團未經 審計營業收入約人民幣497,964萬元，未經審計營業成本約人民幣299,069萬元， 及未經審計歸屬於母公司所有者的淨利潤約人民幣41,626萬元 ...

Core Viewpoint - The "Autumn Market Carnival 2025" held at Xiangshan Hotel integrates traditional Chinese medicine health concepts with the seasonal theme of autumn, showcasing a variety of health products from Tongrentang Technology Company [1][10]. Group 1: Event Overview - The event took place from October 24 to 29, 2025, featuring a vibrant autumn atmosphere with a focus on health and wellness [1]. - Organized by the Beijing Federation of Trade Unions, the event aims to activate consumer vitality and promote resource sharing among enterprises [3]. Group 2: Product Highlights - Star products from Tongrentang Technology include Vitamin E cream, urea cream, and purple grass repair cream, which are popular among returning customers [6]. - The Vitamin E cream, enhanced with ginseng, is particularly sought after for its moisturizing properties during the dry autumn and winter seasons [6]. Group 3: Cultural Integration - The event features cultural products such as Xiangshan leaf dolls and herbal sachets, appealing to both children and adults [8]. - Health foods like Ejiao cake, Ejiao instant powder, and health wines are also highlighted, promoting the concept of "food as medicine" [8]. Group 4: Strategic Vision - The event serves as a platform for integrating traditional health knowledge into everyday life, leveraging the Xiangshan scenic area as a cultural tourism IP [10]. - Tongrentang Technology aims to continue blending health wisdom into various life scenarios, enhancing public health awareness [10].

誠如該公告所披露，載有（其中包括）續訂之銷售框架性協議及續訂之採購框架性協議 及其項下擬進行之持續關連交易之建議年度上限之詳情、獨立董事委員會函件及獨立財 務顧問致獨立董事委員會及獨立股東之意見，連同召開本公司股東特別大會之通告的通 函（「通函」）將適時寄發予股東。 由於本公司需要額外時間完成通函所載資料及安排刊發通函，通函的寄發日期預期將延 遲至二零二五年十一月三十日或之前。 承董事會命 北京同仁堂科技發展股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 ( 於中華人民共和國註冊成立的股份有限公司 ) (股份代號：1666) 延遲寄發通函 茲提述北京同仁堂科技發展股份有限公司（「本公司」）日期為二零二五年九月二十九 日之公告（「該公告」），內容有關續訂銷售框架性協議及採購框架性協議項下擬進行 之持續關連交易。除另行界定外，本公告所用詞彙與該公告所界定者具有相同涵義。 二零二五年十月二十二日 截至本公告日期，董事會包括執行董事張毅先生、張春 ...

Core Viewpoint - The Beijing International Intangible Cultural Heritage Week showcased traditional Chinese medicine practices, particularly the handmade production of Tong Ren Tang's An Gong Niu Huang Wan, highlighting the importance of cultural heritage in modern health practices [1][11]. Group 1: Event Highlights - The event featured a live demonstration of the traditional production techniques of An Gong Niu Huang Wan by Kong Lingjun, a master craftsman, allowing attendees to experience the charm of traditional Chinese medicine [1][11]. - The exhibition included a variety of Tong Ren Tang's major traditional Chinese medicine products, such as Liu Wei Di Huang Wan and Qian Bei Pi Pa Tang, providing visitors with comprehensive health information for the autumn season [9]. Group 2: Audience Engagement - Attendees expressed curiosity and eagerness to participate in the hands-on experience of making medicinal pills, with many finding the process more challenging than expected [5][7]. - Children showed particular interest in the pill-making process, with parents supporting their engagement in traditional culture through hands-on learning experiences [7]. Group 3: Craftsmanship and Training - Kong Lingjun emphasized the importance of skill and precision in the pill-making process, noting that mastering the technique requires at least three years of training to meet GMP standards [11]. - The company focuses on the transmission and development of traditional craftsmanship, ensuring that the skills are passed down to future generations through practical training [11].

Core Insights - The company has successfully completed the medical material reserve task assigned by the Beijing Municipal Drug Administration, reinforcing the logistics support for regional public health emergency guarantees [1][4] - The company is a significant producer of traditional Chinese medicine under the Tongrentang Group, with a portfolio of nearly 200 products, including popular items like Ganmao Qingre Granules and Banlan Gen Granules [1][4] - The company has established a modern warehouse capable of storing 1.31 million units of traditional Chinese medicine products and has a complete intelligent logistics distribution system [1] Group 1 - The company has been recognized as a city-level medical material reserve unit, which tests its ability to fulfill social responsibilities and supply tasks [4] - A total of 460,000 boxes of five product specifications, including Ganmao Qingre Granules and Banlan Gen Granules, have been included in the reserve list [4] - The quality and safety of the reserve materials are crucial for effective emergency support, leading the company to implement a special reserve management and emergency allocation plan [4][6] Group 2 - The logistics distribution center has enhanced protective measures and established a designated area for city-level medical reserves, ensuring compliance and traceability of stored materials [4][6] - The center conducts regular emergency allocation drills every two months to improve operational accuracy and efficiency, ensuring timely delivery during emergencies [6] - The company achieved its "six zero" goals during the task period, including zero quality issues and zero delays in emergency responses [8] Group 3 - The company plans to further develop its system, personnel, and operational processes to enhance the management of medical material reserves and extend these practices to the overall drug management process [8] - The aim is to improve management precision and contribute significantly to public medication safety and regional public health security [8]